PRODUCT SPECIFICATION



HSR 002 Mannan-binding lectin oligomer deficient serum

Human serum

Article No.	36832	
Product Name	HSR 002 Mannan-binding lectin oligomer deficient serum	
Presentation	Preparation: Content: Solvent: Storage:	Undiluted pooled human serum <20 arbitrary unit (AU) oligomer per ml None -18 °C or colder
Preparation	The serum was tested negative for HbsAg and for antibodies against HIV 1, HIV-2 and HCV. Blood from healthy donors with MBL genotype B/B was collected in flasks without anticoagulant and allowed to clot. Serum was collected after centrifugation and pooled. After mixing, 1-ml aliquots of the serum were sub dispensed into 1-ml cryo tubes. The material was frozen at -20 °C.	
Background	Human MBL ¹ is an opsonin, which activates the complement system ² on binding to microbial polysaccharides. Plasma concentrations of normally oligomerized MBL range from 0 to 7000 ng/ml and may be below 50 ng/ml in up to 12% of healthy Caucasian blood donors. Low plasma concentrations may be associated with an inherited opsonin defect ³ . MBL from donors of B/B genotype is poorly oligomerized and gives low readings in MBL assays selective for oligomerized MBL.	
References	1. Kawasaki N, Kawasaki T, Yamashina I (1983) Isolation and characterization of a mannan-binding protein from human serum. J Biochem (Tokyo) 94, 937-947. 2. Turner MW (1998) Mannose-binding lectin (MBL) in health and disease. Immunobiology 199, 327-339. 3. Garred P, Madsen HO, Kurtzhals JA, Lamm LU, Thiel S, Hey AS, Svejgaard A (1992) Diallelic polymorphism may explain variations of the blood concentration of mannan-binding protein in Eskimos, but not in black Africans. Eur J Immunogenet 19, 403-412.	

Conditions

For research use only. Not for use in diagnostic procedures. Not for therapeutic use or applications.

The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall Statens Serum Institut be responsible for loss of profits or indirect consequential losses resulting from use of its products. The animals from which this product was derived have not been exposed to or inoculated with any livestock or poultry disease agents exotic to the United States or Western Europe, and did not originate from facilities where work with exotic disease agents affecting livestock or avian species is carried out.